•   
  •   

MoneyReckitt to pay $1.4 billion to end Indivior probe

13:30  11 july  2019
13:30  11 july  2019 Source:   reuters.com

European Commission launches antitrust probe into Broadcom

European Commission launches antitrust probe into Broadcom European Commission launches antitrust probe into Broadcom

www. indivior .com/. Indivior is a specialty pharmaceuticals business. It is listed on the London Stock Exchange. Reckitt Benckiser has settled with the Justice Department to pay $ 1 . 4 billion to resolve a U.S. Federal investigation into ^ " Reckitt to pay $ 1 . 4 billion to end long-running Indivior probes ".

Britain’s Reckitt Benckiser will pay up to $ 1 . 4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior (INDV.L). The settlement means the British consumer goods giant will have to raise

Reckitt to pay $1.4 billion to end Indivior probe © Reuters/Stephen Hird FILE PHOTO: Products produced by Reckitt Benckiser; Vanish, Finish, Dettol and Harpic are seen in London
(Reuters) - Britain's Reckitt Benckiser will pay up to $1.4 billion (£1.2bn) to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior .

The settlement means the British consumer goods giant will have to raise the amount of money it has set aside to cover the cost of the investigations to $1.5 billion (£1.2bn), from an earlier provision of $400 million (£319m) , the company said on Thursday.

Gardaí launch probe after a woman's body is recovered off the coast of Donegal

Gardaí launch probe after a woman's body is recovered off the coast of Donegal Gardaí launch probe after a woman's body is recovered off the coast of Donegal

Britain's Reckitt Benckiser will pay up to $ 1 . 4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior . Reckitt Benckiser (RB) said it had reached agreements with the U.S. Department.

Reckitt Benckiser Group Plc agreed to pay as much as $ 1 . 4 billion to settle an investigation into the sales and marketing of a treatment for opioid Most of the events under investigation took place before Indivior split from its former parent at the end of 2014. The settlement’s magnitude is more than three

Reckitt Benckiser (RB) said it had reached agreements with the U.S. Department of Justice (DOJ) and the Federal Trade Commission (FTC) to resolve the investigation into a business that was wholly demerged from the company in 2014.

The U.S. Justice Department had accused Indivior of illegally boosting prescriptions for the opioid addiction treatment, called Suboxone Film.

Separately on Thursday, Indivior raised its full-year profit and revenue guidance after Suboxone lost market share at a lower pace than expected, bolstering its first-half performance.

"While RB has acted lawfully at all times and expressly denies all allegations that it engaged in any wrongful conduct, after careful consideration, the board of RB determined that the agreement is in the best interests of the company and its shareholders," the company said in a statement.

Deutsche Bank to cut 18,000 jobs in 7.4 billion euro overhaul

Deutsche Bank to cut 18,000 jobs in 7.4 billion euro overhaul Deutsche Bank to cut 18,000 jobs in 7.4 billion euro overhaul

Britain’s Reckitt Benckiser has agreed to pay up to $ 1 . 4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior (INDV.L). While the settlement is significantly higher than the 0

The settlement, the largest by any company related to the U.S. opioid epidemic, resolved long-running probes by the U.S. Justice Department and the Federal Trade Commission into the companies' marketing and sales of Suboxone Film.

It said the agreement avoided the costs, uncertainty and distraction associated with continued investigations, litigation and the potential for an indictment at a time of significant change for the company, which is undergoing a restructuring plan and handing over to a new chief executive.

"$1.4bn (£1.2bn) is materially larger than the $400m (£319m) RB had previously provisioned and represents c2% of its market cap. On the other hand this settlement removes some uncertainty from the investment case," Credit Suisse analyst Alan Erskine said.

Last month, RB picked PepsiCo executive Laxman Narasimhan as its next CEO, becoming the latest industry heavyweight to turn to a company outsider to tackle faltering growth and new media-savvy rivals.

RB's outgoing boss Rakesh Kapoor launched a plan to split the group into two business units – one for health and one for hygiene and home products - under the same parent company.

RB said the settlement would be funded through existing borrowing facilities and cash generation.

MSN are empowering Women In Sport this summer. Find out more about our campaign and the charity fighting to promote the transformational and lifelong rewards of exercise for women and girls in the UK here.

Lloyds and Standard Life Aberdeen to settle 100 billion sterling funds row: Sky News.
Lloyds and Standard Life Aberdeen to settle 100 billion sterling funds row: Sky News

—   Share news in the SOC. Networks
usr: 4
This is interesting!